

Direct Methyl C(sp³)-H Azolation of Thioanisoles via Oxidative Radical Coupling

Xin Wang,^{a,b} Changhao Li,^a Yixiao Zhang,^a Bing Zhang,^b and Kai Sun^a

^aCollege of Chemistry and Chemical Engineering, Anyang Normal University, Anyang 455000, P. R. China

^bCollege of Chemistry and Energy, Zhengzhou University, Zhengzhou 450001, P. R. China

Corresponding author: sunk468@nenu.edu.cn

Supporting Information

Table of Contents

I. General Remarks.....	S2
II. Synthesis Procedure.....	S2
III. Analytical Data of Compounds 3, 4, 5 and 6	S3
IV. ¹ H NMR, and ¹³ C NMR Spectra of Compounds 3, 4, 5 and 6	S9

I. General remarks.


All reagents were purchased from commercial sources and used without further purification. ^1H NMR and ^{13}C NMR spectra were recorded on a Bruker Ascend™ 400 spectrometer in deuterated solvents containing TMS as an internal reference standard. High-resolution mass spectrometry (HRMS) analyses were conducted on a Waters LCT Premier/XE. Melting points were measured on a melting point apparatus equipped with a thermometer and were uncorrected. All the reactions were monitored by thin-layer chromatography (TLC) using GF254 silica gel-coated TLC plates. Purification by flash column chromatography was performed over SiO_2 (silica gel 200–300 mesh).

II. General procedure:

Synthesis procedure for compounds 3:

To a reaction tube equipped with a stir bar was sequentially added thioanisoles **1** (1.8 mmol), azoles **2** (0.3 mmol) and DBDMH (0.3 mmol, 1.0 equiv.). Then the reaction mixture was stirred in CH_3CN (1.0 mL) at 90 °C. Upon completion of the reaction (as monitored by TLC), the mixture was cooled to room temperature and quenched with water before being extracted with dichloromethane (5×3 mL). The combined organic layers were dried over anhydrous Na_2SO_4 and concentrated under reduced pressure to give a residue, which was purified by flash column chromatography to give the desired product **3**.

Synthesis procedure for compounds 4:



To a reaction tube equipped with a stir bar was sequentially added **3w** (0.5 mmol), and 3-chloroperbenzoic acid (*m*-CPBA, 1.2 equiv). Then the reaction mixture was stirred in CH_2Cl_2 (2.0 mL) at room temperature for 2 hours. Upon completion of the reaction, the mixture was cooled to room temperature and quenched with water before being extracted with dichloromethane (5×3 mL). The combined organic layers were

dried over anhydrous Na_2SO_4 and concentrated under reduced pressure to give a residue, which was purified by flash column chromatography to give the desired product **4** (81%, 104.1 mg).

III. Analytical data of products obtained in this study

2-chloro-1-((phenylthio)methyl)-1*H*-benzo[*d*]imidazole (3a**).** White solid (76%, 62.2 mg), melting point: 96-97 °C; ^1H NMR (400 MHz; CDCl_3): δ = 5.42 (s, 2H), 4.47 (d, J = 7.2, 1H), 7.22-7.28 (m, 6H), 7.34 (d, J = 2.4, 1H), 7.68 (d, J = 7.2, 1H). ^{13}C NMR (100 MHz; CDCl_3): δ = 49.7, 110.3, 119.5, 123.0, 123.3, 129.3, 129.5, 131.0, 134.1, 135.1, 140.4, 141.6. HRMS (ESI-TOF) Calcd for $\text{C}_{14}\text{H}_{12}\text{ClSN}_2$, $[\text{M}+\text{H}]^+$ 275.0411; Found 275.0417.

2-chloro-1-((2-methoxyphenyl)thio)methyl)-1*H*-benzo[*d*]imidazole (3b**).** Colourless liquid (78%, 71.1 mg). ^1H NMR (400 MHz; CDCl_3): δ = 3.69 (s, 3H), 5.44 (s, 2H), 6.79 (t, J = 8.4, 2H), 7.18-7.32 (m, 5H), 7.63 (d, J = 7.6, 1H). ^{13}C NMR (100 MHz; CDCl_3): δ = 47.6, 55.5, 110.1, 110.9, 118.1, 119.3, 121.0, 122.8, 123.1, 131.6, 134.4, 137.3, 140.4, 141.5, 160.1. HRMS (ESI-TOF) Calcd for $\text{C}_{15}\text{H}_{14}\text{ClSON}_2$, $[\text{M}+\text{H}]^+$ 305.0515; Found 305.0519.

2-chloro-1-((2-chlorophenyl)thio)methyl)-1*H*-benzo[*d*]imidazole (3c**).** White solid (64%, 59.3 mg), melting point: 92-93 °C; ^1H NMR (400 MHz; CDCl_3): δ = 5.46 (s, 2H), 7.02 (t, J = 7.6, 1H), 7.10-7.29 (m, 5H), 7.43 (d, J = 8.0, 1H), 7.63 (d, J = 7.6, 1H). ^{13}C NMR (100 MHz; CDCl_3): δ = 47.7, 109.9, 119.5, 123.1, 123.3, 127.4, 129.4, 130.2, 131.2, 134.2, 137.6, 139.5, 140.3, 141.5. HRMS (ESI-TOF) Calcd for $\text{C}_{14}\text{H}_{11}\text{Cl}_2\text{SN}_2$, $[\text{M}+\text{H}]^+$ 309.0021; Found 309.0028.

2-chloro-1-((3-chlorophenyl)thio)methyl)-1*H*-benzo[*d*]imidazole (3d**).** White solid (60%, 55.6 mg), melting point: 99-100 °C; ^1H NMR (400 MHz; CDCl_3): δ = 5.43 (s, 2H), 7.03 (d, J = 7.6, 1H), 7.12-7.26 (m, 2H), 7.27-7.30 (m, 3H), 7.32 (d, J = 8.0, 1H), 7.68 (s, 1H). ^{13}C NMR (100 MHz; CDCl_3): δ = 49.4, 110.1, 119.6, 123.2, 123.4, 129.6, 130.3, 132.8, 132.9, 134.5, 134.8, 140.2, 141.6. HRMS (ESI-TOF) Calcd for $\text{C}_{14}\text{H}_{11}\text{Cl}_2\text{SN}_2$, $[\text{M}+\text{H}]^+$ 309.0021; Found 309.0027.

2-chloro-1-(((4-methoxyphenyl)thio)methyl)-1*H*-benzo[*d*]imidazole (3e).

White solid (74%, 67.7 mg), melting point: 96-97 °C; ¹H NMR (400 MHz; CDCl₃): δ = 3.77 (s, 3H), 5.33 (s, 2H), 6.73 (d, *J* = 8.4, 2H), 7.10 (d, *J* = 8.8, 2H), 7.18 (d, *J* = 8.2, 1H), 7.28 (t, *J* = 5.6, 2H), 7.69 (d, *J* = 7.2, 1H). ¹³C NMR (100 MHz; CDCl₃): δ = 50.1, 55.3, 110.4, 114.8, 119.4, 121.4, 123.0, 123.2, 134.1, 137.1, 140.4, 141.6, 161.0. HRMS (ESI-TOF) Calcd for C₁₅H₁₄ClSON₂, [M+H]⁺ 305.0515; Found 305.0520.

2-chloro-1-(((4-ethoxyphenyl)thio)methyl)-1*H*-benzo[*d*]imidazole (3f). White solid (73%, 69.8 mg), melting point: 61-62 °C; ¹H NMR (400 MHz; CDCl₃): δ = 1.40 (t, *J* = 7.2, 3H), 3.98 (d, *J* = 7.8, 2H), 5.33 (s, 2H), 6.71 (d, *J* = 8.8, 2H), 7.09 (d, *J* = 8.8, 2H), 7.18 (d, *J* = 7.2, 1H), 7.25-7.28 (m, 2H), 7.67 (d, *J* = 7.2, 1H). ¹³C NMR (100 MHz; CDCl₃): δ = 14.6, 50.1, 63.5, 110.4, 115.3, 119.4, 121.1, 123.0, 123.2, 134.1, 137.1, 140.5, 141.6, 160.3. HRMS (ESI-TOF) Calcd for C₁₆H₁₆ClSON₂, [M+H]⁺ 319.0672; Found 319.0677.

2-chloro-1-(((4-fluorophenyl)thio)methyl)-1*H*-benzo[*d*]imidazole (3g). White solid (43%, 37.8 mg), melting point: 52-53 °C; ¹H NMR (400 MHz; CDCl₃): δ = 5.37 (s, 2H), 6.92 (t, *J* = 8.8, 2H), 7.16-7.30 (m, 5H), 7.67 (d, *J* = 7.2, 1H). ¹³C NMR (100 MHz; CDCl₃): δ = 49.8, 110.2, 116.4, 116.6, 119.6, 123.1, 123.3, 126.1, 134.0, 137.5, 137.6, 140.3, 141.6, 162.5, 165.0. HRMS (ESI-TOF) Calcd for C₁₄H₁₁ClFSN₂, [M+H]⁺ 293.0315; Found 293.0310.

2-chloro-1-(((4-chlorophenyl)thio)methyl)-1*H*-benzo[*d*]imidazole (3h). White solid (70%, 64.9 mg), melting point: 110-111 °C; ¹H NMR (400 MHz; CDCl₃): δ = 5.39 (s, 2H), 7.14-7.22 (m, 5H), 7.30 (dd, *J*₁ = 1.2, *J*₂ = 7.6, 2H), 7.68 (d, *J* = 7.2, 1H). ¹³C NMR (100 MHz; CDCl₃): δ = 49.6, 110.2, 119.6, 123.2, 123.4, 129.3, 129.5, 133.9, 136.1, 136.5, 140.3, 141.6. HRMS (ESI-TOF) Calcd for C₁₄H₁₁Cl₂SN₂, [M+H]⁺ 309.0021; Found 309.0024.

1-((4-bromophenyl)thio)methyl)-2-chloro-1*H*-benzo[*d*]imidazole (3i). White solid (64%, 67.9 mg), melting point: 102-103 °C; ¹H NMR (400 MHz; CDCl₃): δ = 5.40 (s, 2H), 7.08 (d, *J* = 8.0, 2H), 7.18 (t, *J* = 7.2, 1H), 7.29 (dd, *J*₁ = 2.0, *J*₂ = 7.2, 2H), 7.38 (d, *J* = 8.4, 2H), 7.69 (d, *J* = 1.2, 1H). ¹³C NMR (100 MHz; CDCl₃): δ = 49.5,

110.2, 119.6, 123.2, 123.4, 124.3, 130.0, 132.5, 133.9, 136.6, 140.3, 141.6. HRMS (ESI-TOF) Calcd for C₁₄H₁₁ClBrSN₂, [M+H]⁺ 352.9517; Found 352.9512.

2-chloro-1-((*p*-tolylthio)methyl)-1*H*-benzo[*d*]imidazole (3j**).** White solid (52%, 45.1 mg), melting point: 95-96 °C; ¹H NMR (400 MHz; CDCl₃): δ = 2.31 (s, 3H), 5.35 (s, 2H), 7.01 (d, *J* = 7.6, 2H), 7.11 (d, *J* = 8.0, 2H), 7.18-7.27 (m, 3H), 7.66 (d, *J* = 7.6, 1H). ¹³C NMR (100 MHz; CDCl₃): δ = 21.1, 49.9, 110.4, 119.4, 123.0, 123.2, 127.4, 130.0, 134.1, 135.1, 139.7, 140.4, 141.6. HRMS (ESI-TOF) Calcd for C₁₅H₁₄ClSN₂, [M+H]⁺ 289.0566; Found 289.0571.

1-((phenylthio)methyl)-2-(trifluoromethyl)-1*H*-benzo[*d*]imidazole (3k**).** White solid (68%, 62.8 mg), melting point: 2-43 °C; ¹H NMR (400 MHz; CDCl₃): δ = 5.54 (s, 2H), 7.17 (d, *J* = 7.6, 1H), 7.23-7.26 (m, 4H), 7.30-7.38 (m, 3H), 7.85 (d, *J* = 8.4, 1H). ¹³C NMR (100 MHz; CDCl₃): δ = 50.4, 111.5, 120.1, 121.6, 123.9, 125.3, 129.3, 129.5, 131.2, 134.7, 135.0, 141.0. HRMS (ESI-TOF) Calcd for C₁₅H₁₂F₃SN₂, [M+H]⁺ 309.0673; Found 309.0667.

1-((4-methoxyphenyl)thio)methyl)-2-(trifluoromethyl)-1*H*-benzo[*d*]imidazole (3l**).** White solid (73%, 74.0 mg), melting point: 67-68 °C; ¹H NMR (400 MHz; CDCl₃): δ = 3.76 (s, 3H), 5.45 (s, 2H), 6.71 (d, *J* = 8.4, 2H), 7.09 (d, *J* = 8.8, 2H), 7.21 (d, *J* = 7.2, 1H), 7.35 (t, *J* = 6.4, 2H), 7.85 (d, *J* = 7.2, 1H). ¹³C NMR (100 MHz; CDCl₃): δ = 50.8, 55.3, 111.7, 114.8, 120.1, 121.5, 123.8, 125.2, 134.7, 137.0, 141.0. HRMS (ESI-TOF) Calcd for C₁₆H₁₄F₃SON₂, [M+H]⁺ 339.0781; Found 339.0776.

1-((4-fluorophenyl)thio)methyl)-2-(trifluoromethyl)-1*H*-benzo[*d*]imidazole (3m**).** White solid (41%, 40.1 mg), melting point: 77-78 °C; ¹H NMR (400 MHz; CDCl₃): δ = 5.50 (s, 2H), 6.93 (t, *J* = 8.4, 2H), 7.17-7.27 (m, 3H), 7.36-7.39 (m, 2H), 7.87 (d, *J* = 6.8, 1H). ¹³C NMR (100 MHz; CDCl₃): δ = 50.5, 111.5, 116.4, 116.6, 121.7, 124.0, 124.3, 125.4, 126.2, 134.6, 137.4, 137.5, 141.0, 162.5, 165.0. HRMS (ESI-TOF) Calcd for C₁₅H₁₁F₄SN₂, [M+H]⁺ 327.0579; Found 327.0573.

1-((4-bromophenyl)thio)methyl)-2-(trifluoromethyl)-1*H*-benzo[*d*]imidazole (3n**).** White solid (59%, 68.5 mg), melting point: 115-116 °C; ¹H NMR (400 MHz; CDCl₃): δ = 5.55 (s, 2H), 7.09 (d, *J* = 8.4, 2H), 7.21 (d, *J* = 7.2, 1H), 7.34-7.86 (m,

4H), 7.87 (d, J = 8.8, 1H). ^{13}C NMR (100 MHz; CDCl_3): δ = 50.1, 111.4, 121.7, 124.0, 124.4, 125.5, 126.5, 130.1, 132.1, 132.5, 136.5, 141.0. HRMS (ESI-TOF) Calcd for $\text{C}_{15}\text{H}_{11}\text{F}_3\text{SBrN}_2$, $[\text{M}+\text{H}]^+$ 386.9779; Found 386.9785.

2-bromo-1-((phenylthio)methyl)-1*H*-benzo[*d*]imidazole (3o). White solid (69%, 66.0 mg), melting point: 98-99 °C; ^1H NMR (400 MHz; CDCl_3): δ = 5.39(s, 2H), 7.14-7.25 (m, 7H), 7.31 (t, J = 2.8, 1H), 7.67 (s, 1H). ^{13}C NMR (100 MHz; CDCl_3): δ = 50.7, 110.4, 119.4, 122.9, 123.2, 129.3, 129.5, 129.8, 130.9, 134.5, 135.3, 143.1. HRMS (ESI-TOF) Calcd for $\text{C}_{14}\text{H}_{12}\text{BrSN}_2$, $[\text{M}+\text{H}]^+$ 318.9905; Found 318.9911.

2-bromo-1-(((4-methoxyphenyl)thio)methyl)-1*H*-benzo[*d*]imidazole (3p). White solid (70%, 73.3 mg), melting point: 52-53 °C; ^1H NMR (400 MHz; CDCl_3): δ = 3.76 (s, 3H), 5.33(s, 2H), 6.72 (d, J = 8.8, 2H), 7.09 (d, J = 8.4, 2H), 7.19-7.25 (m, 3H), 7.68 (d, J = 7.2, 1H). ^{13}C NMR (100 MHz; CDCl_3): δ = 51.1, 55.3, 110.4, 114.8, 119.4, 121.3, 122.9, 123.2, 129.9, 132.9, 134.5, 137.3, 143.1, 161.0. HRMS (ESI-TOF) Calcd for $\text{C}_{15}\text{H}_{14}\text{BrSON}_2$, $[\text{M}+\text{H}]^+$ 349.0010; Found 349.0015.

2-bromo-1-(((4-bromophenyl)thio)methyl)-1*H*-benzo[*d*]imidazole (3q). White solid (65%, 77.6 mg), melting point: 98-99 °C; ^1H NMR (400 MHz; CDCl_3): δ = 5.39 (s, 2H), 7.13 (d, J = 8.4, 2H), 7.19-7.26 (m, 5H), 7.28 (d, J = 5.2, 1H). ^{13}C NMR (100 MHz; CDCl_3): δ = 50.6, 110.3, 119.6, 123.1, 123.4, 129.2, 129.5, 129.8, 134.4, 136.1, 136.7, 143.1. HRMS (ESI-TOF) Calcd for $\text{C}_{14}\text{H}_{11}\text{Br}_2\text{SN}_2$, $[\text{M}+\text{H}]^+$ 396.9010; Found 396.9017.

5-phenyl-1-((phenylthio)methyl)-1*H*-tetrazole (3r). White solid (82%, 65.9 mg), melting point: 68-69 °C; ^1H NMR (400 MHz; CDCl_3): δ = 5.89 (s, 2H), 7.34 (dd, J_1 = 1.2, J_2 = 5.6, 3H), 7.45-7.50 (m, 5H), 8.14 (d, J = 7.6, 2H). ^{13}C NMR (100 MHz; CDCl_3): δ = 56.9, 126.9, 127.1, 128.8, 129.4, 130.4, 131.8, 132.8, 165.6. HRMS (ESI-TOF) Calcd for $\text{C}_{14}\text{H}_{13}\text{SN}_4$, $[\text{M}+\text{H}]^+$ 269.0861; Found 269.0865.

5-(4-chlorophenyl)-1-((phenylthio)methyl)-1*H*-tetrazole (3s). White solid (75%, 68.1 mg), melting point: 66-67 °C; ^1H NMR (400 MHz; CDCl_3): δ = 5.89 (s, 2H), 7.36 (d, J = 5.2, 3H), 7.44-7.48 (m, 4H), 8.07 (d, J = 8.4, 2H). ^{13}C NMR (100 MHz; CDCl_3): δ = 57.0, 124.3, 125.6, 128.2, 128.9, 129.2, 129.4, 131.7, 132.8, 136.5, 164.7. HRMS (ESI-TOF) Calcd for $\text{C}_{14}\text{H}_{12}\text{SClN}_4$, $[\text{M}+\text{H}]^+$ 303.0471; Found 303.0478.

5-(4-bromophenyl)-1-((phenylthio)methyl)-1*H*-tetrazole (3t). White solid (73%, 76.0 mg), melting point: 93-94 °C; ¹H NMR (400 MHz; CDCl₃): δ = 5.89 (s, 2H), 7.35 (d, *J* = 4.8, 3H), 7.43 (d, *J* = 3.6, 2H), 7.63 (d, *J* = 8.4, 2H), 8.00 (d, *J* = 8.4, 2H). ¹³C NMR (100 MHz; CDCl₃): δ = 57.0, 124.9, 126.0, 128.4, 128.9, 129.4, 131.7, 132.1, 132.8, 164.8. HRMS (ESI-TOF) Calcd for C₁₄H₁₂SBrN₄, [M+H]⁺ 346.9966; Found 346.9961.

1-((4-chlorophenyl)thio)methyl)-5-phenyl-1*H*-tetrazole (3u). White solid (75%, 68.1 mg), melting point: 80-81 °C; ¹H NMR (400 MHz; CDCl₃): δ = 5.86 (s, 2H), 7.30 (d, *J* = 8.8, 2H), 7.37 (d, *J* = 8.8, 2H), 7.49-7.52 (m, 3H), 8.14 (t, *J* = 4.4, 2H). ¹³C NMR (100 MHz; CDCl₃): δ = 56.8, 126.7, 126.9, 128.9, 129.6, 130.2, 130.3, 130.6, 134.3, 135.4, 165.7. HRMS (ESI-TOF) Calcd for C₁₄H₁₂SClN₄, [M+H]⁺ 303.0471; Found 303.0477.

1-((4-methoxyphenyl)thio)methyl)-5-phenyl-1*H*-tetrazole (3v). Colourless liquid (74%, 66.2 mg). ¹H NMR (400 MHz; CDCl₃): δ = 3.81 (s, 3H), 5.77 (s, 2H), 6.85 (d, *J* = 8.8, 2H), 7.32-7.37 (m, 2H), 7.49 (dd, *J*₁ = 1.6, *J*₂ = 5.2, 3H), 8.15 (dd, *J*₁ = 2.0, *J*₂ = 7.6, 2H). ¹³C NMR (100 MHz; CDCl₃): δ = 55.3, 58.1, 114.9, 121.9, 123.4, 124.3, 126.9, 128.8, 130.4, 136.0, 165.5. HRMS (ESI-TOF) Calcd for C₁₅H₁₄SON₄, [M+H]⁺ 299.0967; Found 299.0962.

1-((phenylthio)methyl)-1*H*-benzo[d][1,2,3]triazole (3w). White solid (79%, 57.1 mg), melting point: 84-85 °C; ¹H NMR (400 MHz; CDCl₃): δ = 5.95 (s, 2H), 7.21-7.27 (m, 5H), 7.35-7.45 (m, 3H), 8.03 (d, *J* = 8.4, 1H). ¹³C NMR (100 MHz; CDCl₃): δ = 52.7, 110.1, 120.1, 124.1, 127.4, 128.7, 129.3, 131.9, 132.1, 133.0, 146.3. HRMS (ESI-TOF) Calcd for C₁₃H₁₂SN₃, [M+H]⁺ 242.0752; Found 242.0758.

1-((4-chlorophenyl)thio)methyl)-1*H*-benzo[d][1,2,3]triazole (3x). White solid (78%, 64.5 mg), melting point: 96-97 °C; ¹H NMR (400 MHz; CDCl₃): δ = 5.93 (s, 2H), 7.16-7.22 (m, 4H), 7.41 (q, *J* = 4.0, 1H), 7.49 (d, *J* = 3.6, 2H), 8.06 (d, *J* = 8.4, 1H). ¹³C NMR (100 MHz; CDCl₃): δ = 52.5, 109.9, 120.3, 124.2, 127.6, 129.5, 130.1, 134.4, 135.2, 146.4. HRMS (ESI-TOF) Calcd for C₁₃H₁₁SClN₃, [M+H]⁺ 276.0362; Found 276.0371.

1-(((4-bromophenyl)thio)methyl)-1*H*-benzo[*d*][1,2,3]triazole (3y). White solid (77%, 73.9 mg), melting point: 114-115 °C; ¹H NMR (400 MHz; CDCl₃): δ = 5.92 (s, 2H), 7.09 (d, *J* = 8.8, 2H), 7.34-7.42 (m, 3H), 7.48 (d, *J* = 4.0, 2H), 8.05 (d, *J* = 8.0, 1H). ¹³C NMR (100 MHz; CDCl₃): δ = 52.4, 109.9, 120.2, 123.3, 124.3, 127.6, 130.8, 132.0, 132.4, 134.4, 146.4. HRMS (ESI-TOF) Calcd for C₁₃H₁₁SBrN₃, [M+H]⁺ 319.9857; Found 319.9851.

1-((4-methoxyphenyl)thio)methyl)-1*H*-benzo[*d*][1,2,3]triazole (3z). White solid (82%, 66.7 mg), melting point: 107-108 °C; ¹H NMR (400 MHz; CDCl₃): δ = 3.76 (s, 3H), 5.83 (s, 2H), 6.72 (d, *J* = 8.8, 2H), 7.09 (d, *J* = 8.4, 2H), 7.38-7.46 (m, 3H), 8.05 (d, *J* = 8.0, 1H). ¹³C NMR (100 MHz; CDCl₃): δ = 53.7, 55.3, 110.1, 114.8, 120.1, 122.0, 124.1, 127.3, 136.0, 146.3, 160.6. HRMS (ESI-TOF) Calcd for C₁₄H₁₄SON₃, [M+H]⁺ 272.0858; Found 272.0884.


1-((phenylsulfinyl)methyl)-1*H*-benzo[*d*][1,2,3]triazole (4). White solid (81%, 104.1 mg), melting point: 143-144 °C; ¹H NMR (400 MHz; CDCl₃): δ = 5.68 (d, *J* = 13.2, 2H), 7.38 (d, *J* = 7.6, 1H), 7.45-7.56 (m, 7H), 8.02 (d, *J* = 8.4, 1H). ¹³C NMR (100 MHz; CDCl₃): δ = 69.7, 110.0, 120.0, 124.2, 124.5, 128.4, 128.7, 129.5, 132.3, 133.6, 140.1, 145.8. HRMS (ESI-TOF) Calcd for C₁₄H₁₄SON₃, [M+H]⁺ 258.0695; Found 258.0694.

2,6-di-*tert*-butyl-4-((2-chloro-1*H*-benzo[*d*]imidazol-1-yl)methyl)phenol (5). ¹H NMR (400 MHz; CDCl₃): δ = 1.40 (s, 18H), 5.28 (s, 2H), 6.64 (s, 1H), 7.12 (s, 1H), 7.27 (t, *J* = 4.0, 2H), 7.35 (s, 1H), 7.70 (s, 1H). ¹³C NMR (100 MHz; CDCl₃): δ = 69.7, 110.0, 120.0, 124.2, 124.5, 128.4, 128.7, 129.5, 132.3, 133.6, 140.1, 145.8.


1-(2-bromo-1,1-diphenylethyl)-2-chloro-1*H*-benzo[*d*]imidazole (6). ¹H NMR (400 MHz; CDCl₃): δ = 5.02 (s, 2H), 5.43 (d, *J* = 4.4, 1H), 6.82 (t, *J* = 7.6, 1H), 7.17 (t, *J* = 8.0, 1H), 7.39-7.41 (m, 10H), 7.68 (d, *J* = 8.0, 1H). ¹³C NMR (100 MHz; CDCl₃): δ = 39.7, 70.3, 114.3, 119.4, 122.4, 122.7, 128.5, 128.7, 137.1, 141.4, 141.6, 141.7.

IV. ¹H and ¹³C-NMR spectra for compounds 3, 4, 5 and 6


Compound 3a








Compound 3b




Compound 3c




Compound 3d




Compound 3e




Compound 3f





Compound 3g







Compound 3i




Peak assignments for ¹H NMR (ppm):
 7.701, 7.698, 7.681, 7.379, 7.358, 7.309, 7.291, 7.288, 7.273, 7.198, 7.180, 7.176, 7.104, 7.084, 5.404
 2.18, 2.33, 0.97, 2.11, 2.00





ppm


Compound 3j





141.68
140.46
139.79
135.19
134.13
130.09
127.45
123.21
123.01
119.46
110.43




Compound 3k




Compound 3l




Peak assignments:
 0.99, 2.13, 2.02, 1.91, 2.00, 3.02
 3.767, 5.455, 6.715, 6.736, 7.098, 7.120, 7.213, 7.231, 7.273, 7.336, 7.354, 7.370, 7.858, 7.876






Compound 3m







Compound 3n




Compound 30




Compound 3p




Compound 3q




Compound 3r









Compound 3s




Compound 3t





Compound 3u




Compound 3v




Compound 3w




Compound 3x




Compound 3y




Compound 3z



Compound 4





Compound 5



Compound 6

7.700
7.680
7.417
7.391
7.275
7.191
7.171
7.152
6.862
6.859
6.841
6.822
5.453
5.432
5.029



77.32
77.01
76.99
70.37

